Latest Percutaneous coronary intervention Stories

Heart Attack Patients Get Help With Blood Flow Restoration With Mesh-Covered Stent

2012-10-25 11:09:17

Results of the MASTER trial reported at TCT 2012 and published in JACC A clinical trial found that the use of a next generation, micronet, mesh-covered stent demonstrated improved restoration of blood flow to heart tissue, compared to the use of either bare-metal or drug-eluting stents in heart attack patients undergoing angioplasty. Results of the MASTER trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium and will appear in...

FFR-Guided PCI Shows Cost-Effectiveness When Compared To Medical Therapy For Stable CAD

2012-10-25 11:05:00

Results of the FAME 2 Cost-Effectiveness Trial Presented at TCT 2012 A strategy of up-front percutaneous coronary intervention (PCI) for lesions confirmed to be obstructive by fractional flow reserve (FFR) was shown to be cost-effective in terms of quality-adjusted life years when compared to medical therapy alone. Results of the Cost-Effectiveness sub study of the FAME 2 trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium....

Reported at TCT 2012: InspireMD MGuard Stent Meets Primary Endpoint of MASTER Trial, Significantly Improving Prospects of Heart Attack Survival

2012-10-24 11:26:50

MIAMI, October 24, 2012 /PRNewswire/ -- InspireMD, Inc. (OTC: NSPR) ("InspireMD" or the "Company"), announced its proprietary MGuard(TM) Embolic Protection Stent (EPS) was shown to be significantly superior when compared to standard bare metal and drug eluting stents in achieving complete ST resolution and restoring normal blood flow in a major study of 432 randomized patients undergoing emergency coronary intervention for potentially fatal heart attacks. The data was...

Micell Technologies Announces Positive Data from Clinical Studies of MiStent SES

2012-10-23 15:24:23

DURHAM, N.C., Oct. 23, 2012 /PRNewswire/ -- Micell Technologies, Inc. today announced positive data from two clinical studies of its investigational MiStent(®) Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(TM)), a thin-strut drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed to control drug release. Eighteen-month outcomes from the DESSOLVE I trial, and nine-month data supporting all study endpoints in the DESSOLVE II...

Robotic-Assisted PCI Takes The Stage At TCT 2012

2012-10-18 11:25:28

NATICK, Mass., Oct. 18, 2012 /PRNewswire/ -- Corindus Vascular Robotics, a developer of precision vascular robotics, today announced leading experts in interventional cardiology will speak about their clinical experience using the CorPath(®) 200 System at this year's Transcatheter Cardiovascular Therapeutics' annual meeting, TCT 2012. (Photo: http://photos.prnewswire.com/prnh/20121018/NE95678-a )(Logo: http://photos.prnewswire.com/prnh/20121018/NE95678LOGO-b ) As part of TCT's...

New Survey Shows Heart Patients' Quality of Life Significantly Improved After Angioplasty Procedure

2012-10-17 07:26:36

WASHINGTON, Oct. 17, 2012 /PRNewswire/ -- Today, the Society for Cardiovascular Angiography and Interventions (SCAI) announced results from a new survey that found four out of five (81 percent) patients say their lives have changed for the better following angioplasty, a procedure to open blocked arteries and allow blood to circulate freely. Simultaneously, SCAI published a comprehensive review of research on quality of life following angioplasty and stenting. The paper offers...

National Summit on Overuse References ACE Accreditation as a Cath Lab Quality Assurance Tool

2012-10-11 04:03:11

Presentation on Stents and PCI by Carl L. Tommaso, MD includes ACE as a Solution to Overuse Oakbrook Terrace, Illinois (PRWEB) October 10, 2012 Methods to reduce the occurrence of medical treatments that are not always necessary were presented at the National Summit on Overuse co-sponsored by the American Medical Association (AMA) and The Joint Commission, on September 24, 2012. The summit goal was to discuss strategies to improve the quality and safety of patient care. Representatives...

Public Reporting Affects Rate Of Angioplasty Procedures Following Heart Attacks

2012-10-10 12:24:03

Connie K. Ho for redOrbit.com – Your Universe Online Heart attacks can happen at any moment. They might be triggered by a factor related to diet or exercise, but the question remains as to what happens to patients following treatment. Recently, researchers from Harvard School of Public Health (HSPH) ventured on a mission to analyze data pooled from 100,000 Medicare patients who had suffered a heart attack and the effects that public reporting might have on percutaneous coronary...

Boston Scientific Launches Emerge(TM) PTCA Balloon Dilatation Catheter in the U.S.

2012-09-27 02:27:23

NATICK, Mass., Sept. 27, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration clearance for the Emerge(TM) Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Dilatation Catheter and has begun marketing the device in the United States. The Emerge Catheter is a next-generation pre-dilatation balloon catheter designed specifically to offer exceptional deliverability for physicians to address challenging lesions in...

Results of InspireMD's MASTER Stent Trial Scheduled for Late Breaking Trials Session at TCT in Miami, FL Oct. 24

2012-09-27 02:27:19

TEL AVIV, Israel, September 27, 2012 /PRNewswire/ -- Trial Studied Performance Of MGuard(TM) Embolic Protection Stent (EPS) In 433 Patients Undergoing Emergency Treatment For Heart Attacks InspireMD, Inc. (OTCBB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary MGuard(TM) embolic protection stent platform technology for use in patients with Acute Myocardial...